TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03498404

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: scaling and root planing
Description: Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
Study: NCT00475956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet multiple ascending doses 20, 30 or 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet multiple ascending doses 20, 30 or 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet multiple ascending doses 125 mg or 175 mg
Study: NCT02291458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 9 gram L-arginine / day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 gram placebo / day for 6 weeks
Study: NCT01470950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motionmaker
Description: 3 times per week, FES Training on the Motionmaker device, for 6 months
Study: NCT02817568

Intervention type: OTHER
Intervention: Drawing Blood
Description: Drawing Blood for genetic analysis

Intervention type: OTHER
Intervention: Drawing Blood
Description: Drawing Blood for genetic analysis
Study: NCT04395742

Intervention type: OTHER
Intervention: Data collection
Description: Only data collection

Intervention type: OTHER
Intervention: Data collection
Description: Only data collection
Study: NCT00867815

Intervention type: DRUG
Group type: OTHER
Intervention: Diagnostic procedures
Description: The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
Study: NCT00245752

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
Study: NCT04326283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (0.5 mg)
Description: 0.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (1 mg)
Description: 1 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole (100 mg)
Description: 100 mg/day (50 mg twice)
Study: NCT04182646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartz Balloon
Description: The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
Study: NCT00273793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.
Study: NCT00140582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Study: NCT04424264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid
Description: TDF/FTC/EFV 300/200/600 mg once daily plus RIF/INH 600\*/300 mg daily from screening until enrolment (days -15 to 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid
Description: TAF 25 mg + 3TC 300 mg + EFV 600 mg once daily plus RIF/INH 600/\*300 mg daily (days 1 to ≤ 56)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
Description: TDF/FTC/EFV 300/200/600 mg once daily. RIF/INH 600mg \<70kg, 750mg \>70kg
Study: NCT01380821

Intervention type: RADIATION
Intervention: Myocardial SPECT
Description: Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
Study: NCT04129008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen and aspirin mimetic
Description: Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and indobufen mimetic
Description: Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
Study: NCT00487461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Description: Comparing two doses of Simvastatin to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Description: Comparing two doses of Simvastatin to placebo
Study: NCT00619814

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-contrast Barium enema, colonoscopy
Description: This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
Study: NCT01544335

Intervention type: OTHER
Intervention: Bioimpedance Spectroscopy
Description: BIS used to measure fluid in arm
Study: NCT00350415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks
Study: NCT03139591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine inhalation; intravenous dexamethasone
Description: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine inhalation; intravenous dexamethasone
Description: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
Study: NCT01752777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infectiousness Risk Reduction
Description: Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General Health Improvement
Description: Educational counseling to help link participants to social serves and health related strategies.
Study: NCT03198507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-105
Description: The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Study: NCT03565094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996 solution
Description: Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996 capsule
Description: hard capsule orally QD: one dose lower than the highest dose level in part A
Study: NCT00241839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium chloride
Description: Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium chloride
Description: Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
Study: NCT00872443

Intervention type: OTHER
Intervention: Data collection
Description: Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI.
Study: NCT01907035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive-behavioral intervention
Description: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT03193099

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Volume, DWS and DTI

Intervention type: OTHER
Group type: OTHER
Intervention: Brain imaging
Description: Volume, DWS and DTI

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessments
Description: UHDRS

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological assessments
Description: UHDRS

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological assessments
Description: STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological assessments
Description: STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural assessments
Description: Computerized game

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioural assessments
Description: Computerized game
Study: NCT04041414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proud & Empowered!
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proud & Empowered!
Description: Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
Study: NCT01411891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine impregnated patch (Biopatch)
Description: Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
Study: NCT02559024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
Study: NCT01121770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium injection
Description: 1.5mg subcutaneously every day
Study: NCT01531569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BeneFlax - 38% secoisolariciresinol diglucoside (SDG)
Description: 0.8g of BeneFlax (contains 300mg SDG) given once by mouth
Study: NCT02406508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT01059435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered subcutaneously or intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously or intravenously
Study: NCT02865213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBA
Description: The intrusion of posterior teeth using removable appliance OBA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBA
Description: The intrusion of posterior teeth using removable appliance OBA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OBA
Description: The intrusion of posterior teeth using removable appliance OBA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniplates
Description: The intrusion of posterior teeth using temporary anchorage Miniplates.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrews
Description: The intrusion of posterior teeth using temporary anchorage Miniscrews.
Study: NCT01765257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZILECT®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01153334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
Study: NCT04686669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 capsule formulation
Description: FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219 tablet formulation
Description: FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.
Study: NCT02153749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Regulation of Craving
Description: Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Regulation of Craving
Description: Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical.